EP0826040A1 - PROTEINE A CHOC THERMIQUE CANDIDA, ADNc ET UTILISATIONS DE CETTE PROTEINE - Google Patents

PROTEINE A CHOC THERMIQUE CANDIDA, ADNc ET UTILISATIONS DE CETTE PROTEINE

Info

Publication number
EP0826040A1
EP0826040A1 EP96914385A EP96914385A EP0826040A1 EP 0826040 A1 EP0826040 A1 EP 0826040A1 EP 96914385 A EP96914385 A EP 96914385A EP 96914385 A EP96914385 A EP 96914385A EP 0826040 A1 EP0826040 A1 EP 0826040A1
Authority
EP
European Patent Office
Prior art keywords
ala
gly
lys
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96914385A
Other languages
German (de)
English (en)
Inventor
Antonio Cassone
Roberto La Valle
Carla Bromuro
Andrea Universita degli Studi di Roma CRISANTI
Hans M. Universita degli Studi di Roma MÜLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanita ISS
Universita degli Studi di Roma La Sapienza
Original Assignee
Istituto Superiore di Sanita ISS
Universita degli Studi di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanita ISS, Universita degli Studi di Roma La Sapienza filed Critical Istituto Superiore di Sanita ISS
Publication of EP0826040A1 publication Critical patent/EP0826040A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention concerns the cDNA and the corresponding protein of a heat shock protein isolated from C. albicans, and fragments thereof to develop methods to identify C. albicans in biological and/or environment samples, and/or preparations either for therapeutic, prophylaxis or vaccine purpose.
  • Pathogenic yeasts are the major agents of opportunistic infections in immunosuppressed patients, in particular AIDS, tumor, neutropenia patients or bone marrow transplanted subjects (1) .
  • HIV * subject susceptibility to C. albicans is related to the strong decrease of cell-mediated immunity because of the numerical and functional decrease of CD4 + helper-inducer lymphocytes (2) .
  • the authors of the instant invention isolated the caRLV130 clone from an expression library in the ⁇ gtll phage obtained by cDNA isolated from C. albicans at the yeast growth stage. Said clone contains a DNA insert of 2325 base pairs which codes in the 5'-3' direction from +105 to +2072 for a 656 aminoacid protein having a strong homology with a S. cerevisiae heat shock protein 70.
  • HSPs are induced by different stresses, either chemical or physical, normally by heating. Many HSPs are present and active also in non stressed cells, where they play important functions of cell physiology
  • HSPs reactive oxygen species
  • HSPs may be grouped in families of different molecular weights, very conserved even among phylogenesis distant organisms (5) . Therefore it should not be surprising either that HSPs are involved in the immune response, or that they represent major antigens of different pathogenic agents, or that they may give autoimmune responses, given to the fact that the infection itself represents an extreme form of stress, both for the infectious agent and for the host (4) .
  • nucleic acid comprising a nucleotide sequence coding the protein having the amino acid sequence of SEQ ID No.2 or parts thereof.
  • nucleic acid comprises a nucleotide sequence with at least a 65% homology with the nucleotide sequence of SEQ ID No.l or parts thereof. More preferably the nucleic acid comprises the nucleotide sequence of SEQ ID No.l or parts thereof.
  • composition comprising a nucleic acid comprising a nucleotide sequence coding the protein having the amino acid sequence of SEQ ID No.l or parts thereof.
  • the composition comprises a nucleic acid having a nucleotide sequence with at least a 65% homology with the nucleotide sequence of SEQ ID No.l or parts thereof. More preferably the composition comprises a nucleic acid having the nucleotide sequence of SEQ ID No.l or parts thereof.
  • nucleic acid comprising a nucleotide sequence coding the protein having the amino acid sequence of SEQ ID No.2 or parts thereof for oligonucleotide probes to be used in diagnosis and typing of Candida related pathologies.
  • the use of a nucleic acid having at least a 65% homology with the nucleotide sequence of SEQ ID No.l or parts thereof is preferred.
  • the use of a nucleic acid having the nucleotide sequence of SEQ ID No.l or parts thereof is most preferred.
  • the oligonucleotides of the invention are advantageously used for PCR (polymerase chain reaction) to detect the presence in biological and/or environment samples either of C. albicans or of other Candida species or of yeast-like related microorganisms comprising said gene; in a labeled form (radionuclides, biotin, enzymes, etc.) to detect the presence in biological and/or environment samples either of C. albicans or of other related; for the C. albicans or related species typing and/or diagnosis; as potential antibiotic and/or chemiotherapic targets, or antisense RNA active for Candida species and/or, yeast-like related microorganisms coding an homologous sequence.
  • PCR polymerase chain reaction
  • Another object of the invention is a polypeptide having the aminoacid sequence comprised in the SEQ ID No.2, or having at least a 50% homology with SEQ ID No. 2 or fragments, and/or functional and immunologic homologous thereof.
  • composition comprising a polypeptide having an amino acid sequence comprised in SEQ ID No.2 or having at least a 50% homology with SEQ ID No. 2 or fragments, and/or functional and immunologic homologous thereof.
  • HSP70 heat shock protein
  • polypeptide having the amino acid sequence comprised in SEQ ID No.2 or having at least a 50% homology with SEQ ID No. 2 or of fragments, and/or functional and/or immunologic homologous thereof for the preparation of a composition to be used for prophylaxis and/or therapy of C. albicans or related microorganisms (pathogenic yeasts) diseases.
  • Figure 1 represents the 1971 base pair DNA sequence (small letters) corresponding to the open reading frame of ⁇ gtll- (caRLAl30) clone insert and deduced aminoacid sequence (capital letters one-letter code) .
  • Figure 2 represents the nucleotide sequence of the coding insert of caRLV130 clone (small letter) and comparison with S. cerevisiae YSCSSA1 gene (capital letter) .
  • Figure 3 represents the 656 aminoacid sequence deduced from the coding insert of caRLV130 clone (small letter) and comparison with the S. cerevisiae YSCSSA1 gene (capital letter) .
  • the aminoacid code utilized is the one letter code.
  • Figure 4 represents in panel A. Southern blot analysis of C. albicans strain ATCC 20955 chromosomes, obtained by pulse field electrophoresis (TAFE) .
  • the caRLV130 probe labeling refers to the highest molecular weight chromosome (3.5 Mbp) .
  • panel B Electrophoretic separation of C. albicans strain ATCC 20955 chromosomes.
  • Figure 5 represents on the left side: Northern blot analysis by hybridization of total RNA extracted from C. albicans cells grown at 22°C and transferred at 37°C for the time indicated with radiolabeled caRLV130 (cahsp70) and actin probes. The actin probe hybridization was performed to control the RNA amount on filters (see ref. 8) .
  • On the right side immunoblotting reactivity of anti- CAHSP70 mouse serum with C. albicans extracts, at different times further to inducing a heat shock response as previously described.
  • Figure 6 represents in panel A. SDS-PAGE analysis: a) expression products of E. coli M15 containing the pDS5 ⁇ /RBS-E " -6his caRLV130/l plas id; b) expression products of E. coli M15 containing the pDS56/RBS-E " -6his caRLV130/2 plasmid; c) expression products of E. coli M15 containing the pDS56/RBS-E " -6his caRLV130/3 plasmid; d) expression products of E. coli M15 containing the pDS56/RBS-E " -6his caRLV130/4 plasmid.
  • N.I. Non induced E. coli culture extracts.
  • Figure 7 represents the reactivity after immunoblotting on nitrocellulose filters of mouse sera as shown in the figure obtained against CAHSP70 fragments; a) expression products of nickel column purified pDS56/RBSII-E " -6his caRLV130/l plasmid in 1 mM IPTG induced E. coli; b) expression products of nickel column purified pDS56/RBSII-E " -6his caRLV130/2 plasmid in 1 mM IPTG induced M15 E. coli; c) expression products of nickel column purified pDS56/RBSII-E " -6his caRLV130/3 plasmid in 1 mM IPTG induced M15 E.
  • Figure 8 represents the reactivity after immunoblotting on nitrocellulose filters of wealthy human sera obtained against CAHSP70 and fragments thereof; a) expression products of nickel column purified pDS56/RBSII-E " -6his caRLV130/l plasmid in 1 mM IPTG induced M15 E. coli; b) expression products of nickel column purified pDS56/RBSII-E " -6his caRLV130/2 plasmid in 1 mM IPTG induced M15 E. coli; c) expression products of nickel column purified pDS56/RBSII-E " -6his caRLV130/3 plasmid in 1 mM IPTG induced M15 E.
  • Figure 9 represents in panel A. PCR experiment performed using oligonucleotide combination CA2-CA3 in the presence of C. albicans, C. parapsilosis (2) , C. glabrata (3), C. guillermondii (4) , C. krusei (5), C_;_ tropicalis (6), Mus muris (7), E. coli (8), S. cerevisiae (9) DNAs. Control with no DNA is as (10). At the right side the molecular weight of the amplified fragment is indicated.
  • panel B PCR experiment using the combination of CA1-CA4 oligonucleotides in the presence of C. albicans cDNA: DNA amplified from C.
  • PCR reaction conditions are as follows: 90 sec. 94°C denaturation; 90 sec. 60°C annealing; 120 sec. 72°C extension; 25 cycles.
  • Figure 1 shows the 1971 bp coding region of the isolated gene.
  • the caRLV130 sequence was filed with EMBL data base (No. Z30210) . No intron can be found in the intronic sequence, as shown by PCR product analysis and by ⁇ Southern-blot". By comparing the caRLV130 insert sequence with sequences present in the 6.7 version "GENE BANK" data base, some homologies can be detected. The insert shows the most high homology with the S ⁇ cerevisiae gene SSAl (one of the nine heatshock yeast gene family) . The overall nucleotide sequence homology is of 78.8% in the coding region (figg. 2 and 3).
  • the gene corresponding to the caRLV130 sequence was mapped on the C. albicans chromosome showing the highest molecular weight (3.5 Mpb) by pulse field electrophoresis (transverse-alternate: TAFE) utilizing the caRLV130 labeled cDNA insert as hybridization probe with C. albicans chromosomes blotted on nitrocellulose filters (fig. 4A an 4B) .
  • TAFE pulse field electrophoresis
  • TAFE reverse-alternate
  • Gene transcription is activated by exposing cells to a temperature higher than room temperature (thermal shift from 22°C to 37°C) . Such finding was demonstrated by hybridization experiments using C.
  • albicans total RNA from cells grown either at 22°C or at 37°C, fractionated according to molecular weight on formaldehyde agarose gel and blotted on nitrocellulose -filters
  • the induction of transcription is coupled also to an increase of protein expression, 2, 6 and 24 hours further to the 22°C to 37°C temperature shift (see fig. 5) .
  • Peptides are coded by pDS56/RBSII-E " -6his recombinant plasmids wherein caRLV130 fragments were cloned.
  • the position refers to nucleotide and aminoacid sequences as shown in Fig. 1.
  • the peptide length refers to the fusion product coded by the recombinant plasmid.
  • recombinant peptides were used as immunogens to produce mouse immune sera and are therefore able also to induce monoclonal antibodies.
  • polypeptides and the whole purified protein as well, induce specific antibodies in a 18-22 g weight
  • the indicated immunogen concentration was inoculated intraperitoneally in a 200 ⁇ l volume.
  • the titer was determined by indirect ELISA with the antigen used for coating at a 200 ng/well concentration, in a final volume of 100 ⁇ l, and represents the highest serum dilution able to give an ELISA positive reaction (optical density at 405 n > two fold the no antigen control value) .
  • Serum titers for each antigen resulted to be > 12.800 by immunoenzyme test (indirect ELISA) with the adsorbed antigen at 200 ng/well, in a final volume of 100 ⁇ l.
  • immunoenzyme test direct ELISA
  • the specificity of immunoenzyme test results were confirmed in immunoblot experiments on nitrocellulose filters, as shown in Fig. 7.
  • lymphoproliferative activity " " ⁇ -thymidine uptake
  • cord blood 1 cord blood 2 none 2.5 ⁇ 0.4 1.3 ⁇ 0.3
  • CAHSP70 the C. albicans protein having the following properties: I) it comprises the aminoacid sequence coded by the caRLV130 insert; II) its gene maps on C.
  • albicans chromosome 1 (having the highest molecular weight); III) its expression is induced by temperature shift; IV) it induces specific antibodies able to recognize cloned and purified fragments (subunits) ; V) it induces a lymphoproliferation in lymphomonocytic cultures from peripheral human blood.
  • the relevant gene was named as cahsp70.
  • CAHSP70 cloning allows to develop a diagnostic molecular method based upon the amplification of DNA inserts corresponding to caRLV130, other than immunological studies of C. albicans 70 kDa heat shock protein expression.
  • caRLV130 insert sequence we have synthesized oligonucleotides which were utilized for polymerase chain reaction (PCR) experiments, to analyze their ability to amplify DNA fragments which are homologous to C. albicans caRLV130 DNA.
  • PCR polymerase chain reaction
  • Two oligonucleotides were chosen in the regions showing the minimal homology between the caRLV130 cDNA sequence and known HSP70 coding gene sequences (see Fig.
  • GGT AAA CCA GTG ATT CAA GTT GAA TAT AAA GGT GAA ACT AAA ACT TTT 336 Gly Lys Pro Val He Gin Val Glu Tyr Lys Gly Glu Thr Lys Thr Phe 100 105 110
  • GGT GGG TCC ACC AGA ATT CCA AAG ATT CAA AAA TTG GTT TCT GAT TTC 1056
  • MOLECULE TYPE protein

Abstract

Cette invention se rapporte à une séquence de nucléotides et à la protéine associée, tirées de Candida, homologues d'une protéine à choc thermique de 70 kd, conçues pour être utilisées à des fins diagnostiques et thérapeutiques.
EP96914385A 1995-05-16 1996-05-15 PROTEINE A CHOC THERMIQUE CANDIDA, ADNc ET UTILISATIONS DE CETTE PROTEINE Withdrawn EP0826040A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT95RM000314A IT1282287B1 (it) 1995-05-16 1995-05-16 La sequenza del dna completo dell'inserto carlubo codificante per una proteina heat shch di forda (cansp 70) di candida albicans ceppo atcc
ITRM950314 1995-05-16
PCT/IT1996/000097 WO1996036707A1 (fr) 1995-05-16 1996-05-15 PROTEINE A CHOC THERMIQUE CANDIDA, ADNc ET UTILISATIONS DE CETTE PROTEINE

Publications (1)

Publication Number Publication Date
EP0826040A1 true EP0826040A1 (fr) 1998-03-04

Family

ID=11403371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96914385A Withdrawn EP0826040A1 (fr) 1995-05-16 1996-05-15 PROTEINE A CHOC THERMIQUE CANDIDA, ADNc ET UTILISATIONS DE CETTE PROTEINE

Country Status (4)

Country Link
EP (1) EP0826040A1 (fr)
AU (1) AU5777696A (fr)
IT (1) IT1282287B1 (fr)
WO (1) WO1996036707A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11103862A (ja) 1997-10-01 1999-04-20 Takara Shuzo Co Ltd 抗原タンパク質及び該タンパク質をコードする核酸
GB9817796D0 (en) * 1998-08-14 1998-10-14 Janssen Pharmaceutica Nv Drug targets in candida albicans
AU773378B2 (en) * 1998-12-04 2004-05-20 Janssen Pharmaceutica N.V. Drug targets in candida albicans
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US7015309B1 (en) 1999-06-23 2006-03-21 The Wistar Institute Of Anatomy And Biology Pyrrhocoricin-derived peptides, and methods of use thereof
CA2398808A1 (fr) * 2000-01-21 2001-07-26 The Wistar Institute Of Anatomy & Biology Molecules biocides, cibles macromoleculaires, et procedes de production et d'utilisation
EP1209242A3 (fr) * 2000-11-21 2004-01-14 Tosoh Corporation Oligonucléotides et procédé de détection de groupe II SRSV

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9636707A1 *

Also Published As

Publication number Publication date
AU5777696A (en) 1996-11-29
IT1282287B1 (it) 1998-03-16
WO1996036707A1 (fr) 1996-11-21
ITRM950314A0 (it) 1995-05-16
ITRM950314A1 (it) 1996-11-16

Similar Documents

Publication Publication Date Title
Kovacs et al. Multiple genes encode the major surface glycoprotein of Pneumocystis carinii.
Lecordier et al. Characterization of a dense granule antigen of Toxoplasma gondii (GRA6) associated to the network of the parasitophorous vacuole
Prabhakar et al. Identification of an immunogenic histone-like protein (HLPMt) ofMycobacterium tuberculosis
CA2481232A1 (fr) Peptides de replikine utilises dans la replication rapide de cellules de gliome et dans les epidemies de grippe
JP2002223783A (ja) ピーナッツアレルゲンおよび方法
CA2202504C (fr) Peptides de synthese et vaccins les contenant
JPH06504909A (ja) 結核の診断及び抑制に用いるマイコバクテリウムポリペプチド及びそれをコードする核酸
WO2001021804B1 (fr) Antigenes de chlamydia, fragments d'adn correspondants et utilisations
JPS6119490A (ja) 原虫類抗原用ｄｎａのクロ−ニング
KR100906102B1 (ko) 레플리킨 펩타이드 및 그의 이용
WO2002085093A2 (fr) Peptides de replikine et leur utilisation
AU8311291A (en) Allergens of alder pollen and applications thereof
WO1996036707A1 (fr) PROTEINE A CHOC THERMIQUE CANDIDA, ADNc ET UTILISATIONS DE CETTE PROTEINE
McKean et al. Nucleotide sequence analysis and epitope mapping of the merozoite surface protein 1 from Plasmodium chabaudi chabaudi AS
US6024958A (en) Polypeptide fragments capable of competition with Streptococcus mutans antigen I/II
AU706367B2 (en) New DNA molecules
Thomas et al. The hsp60 gene of the human pathogenic fungus Coccidioides immitis encodes a T-cell reactive protein
CN100415895C (zh) gp350/220的非剪接变异体
McCardell et al. Cloning, expression and characterization of the CHO cell elongating factor (Cef) from Vibrio cholerae O1
US20030124124A1 (en) Therapeutic modulation of chemokines using a helminth parasite chemokine-binding protein
EP0656063A1 (fr) Sequences nucleotidiques codant les proteines de cryptosporidius, polypeptides codes par lesdites sequences et leurs materiels d'utilisation
Yoo et al. The ureidoglycollate hydrolase (DAL3) gene in Saccharomyces cerevisiae
WO1994020536A1 (fr) Methodes, compositions et trousses pour le diagnostic de la maladie de lyme
US5459063A (en) Plasmodium falciparum ribonucleotide reductase DNA
Rondinelli Conservation of heat-shock proteins in Trypanosoma cruzi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031001

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031201